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Background
Fibrinogen is a 340 kDa homodimeric plasma glycoprotein, composed of three pairs of polypeptide chains, denoted A , B and , linked together by 29 disulphide bonds 1 . A common variant of the fibrinogen is produced by alternative splicing of mRNA of the -chain, called '
The ' isoform has a substitution of the final 4 carboxyl-terminal amino acid residues (AGDV) of the prevalent A-chain with a different 20-amino acid residue sequence (VRPEHPAETEYDSLYPEDDL), which includes a high proportion of negatively charged residues and two sulfated tyrosines. This variant accounts for 8-15% of all plasma fibrinogen, largely in the form of the heterodimer A ', while the homodimer ' ' accounts for less than 1%
of total plasma fibrinogen 3 . ' fibrinogen has distinct biochemical and biophysical properties that distinguish it from the more common A isoform 4, 5, 6 . Studies have highlighted that abnormal plasma levels of A ' fibrinogen are associated with thrombotic diseases, such as coronary artery disease 7 , myocardial infarction 8 and stroke 9 . Elevated levels of ' fibrinogen in patients with cardiovascular disease (CVD) were independent of the total plasma fibrinogen concentration 7 . This could indicate that the proportion of ' variant in plasma may be a risk factor for cardiovascular pathologies. However, reduced concentrations have been associated with microangiopathy syndrome 10 and deep vein thrombosis 11 . Studies by Appiah et al. did not support the hypothesis that ' fibrinogen influences CVD events through its prothrombotic properties. Rather, ' fibrinogen concentrations seem to reflect general inflammation that accompanies and may contribute to atherosclerotic CVD, instead of ' fibrinogen being a causal risk factor 12 . In addition to this, Walton et al. found that elevated levels of A A fibrinogen promoted arterial thrombosis in vivo, whereas A ' fibrinogen did not 13 . Nevertheless, as ' chain modulates clot formation in vitro, further studies are required to elucidate its functional properties and its possible relationship with bleeding disorders or thrombosis.
The formation of a thrombus and subsequent impairment of blood flow to vital organs are the immediate cause of CVD events 14 . The architecture of the clot network affects clot stability, particularly its viscoelastic or mechanical properties and fibrinolytic characteristics 15, 16 . These
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4 aspects can determine if the clot is broken down by fibrinolysis or if it will lead to occlusion or embolization 17 . Other studies have indicated the clinical relevance of fibrin clot structure. It has been shown that tightly packed and rigid clots with thinner fibers and low porosity are less susceptible to the action of thrombolytic agents 18, 19 , and a prolonged clot lysis time has been associated with CVD events 20 . Several studies have shown that clots produced from A '
fibrinogen have a different structure and behave differently from A A clots 4, 5, 6 . Fibrin clots formed in the presence of the fibrinogen ' variant are more resistant to fibrinolysis, due to reduced binding of plasminogen and tissue plasminogen activator, leading to reduced plasmin generation 21 . Fibrinogen ' variant is associated with a heterogeneous, non-uniform clot structure, with more branch points than clots formed by A chains 6, 22, 23 .In addition, ' fibrinogen binds to thrombin exosite II 24 . The binding of thrombin to the ' chain has been reported to modulate thrombin activity, particularly towards substrates that require exosite II interaction such as coagulation factors FV and FVIII (but not those dependent on exosite I
interactions, e.g. fibrinogen and factor FXIII), which may influence clot structure 6 . However, some of the effects of ' fibrinogen on clot structure have been shown to be independent of thrombin, as clots produced with snake venom enzyme ancrod, which cleaves fibrinopeptide A from fibrinogen but not fibrinopeptide B, show similar structural abnormalities as those produced with thrombin 22 . On the other hand, it has been shown that the high affinity binding of thrombin to A '-fibrin protects thrombin from inhibition by antithrombin, raising the possibility that A '-fibrin serves as a scavenger and reservoir for thrombin in the clot 25 .
Fibrinogen is thought to contribute to CVD, not only through altering the fibrin network structure, but also through several other mechanisms, such as promoting red blood cell (RBC) aggregation 26 . Although several studies on isolated fibrin clots have been performed, in vitro experiments using fibrin blood clots containing RBCs are scarce in the literature. RBCs play a role in blood coagulation by increasing blood viscosity, which is associated with propensity for clot formation 27 . RBCs have been shown to interact specifically with fibrinogen, with ca.20,000
binding sites per RBC and a dissociation constant, K d , of approximately 1.3 µM 28 . We have identified a specific receptor for fibrinogen on the surface of RBCs 29, 30, 31 .
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Despite their significance in thrombosis and hemostasis, relatively few studies have been conducted to describe the effects of RBCs on blood clot structure, particularly with different fibrinogen variants. One complication of studying RBC-rich thrombi is that incorporation of RBCs into a thrombus seems uncontrolled and variable. This scarcity may also be, in part, due to the fact that the presence of RBCs in a clot often interferes with the techniques available to monitor clot structure 32 .
The present study aimed to investigate, through atomic force microscopy-based force spectroscopy, the adhesion of RBCs in the presence of A A or A ' fibrinogen variants.
Moreover, we aimed to understand the effect of RBC-A ' fibrinogen interactions on fibrin clot structure, properties and function through scanning electron microscopy, laser scanning confocal microscopy, magnetic tweezers and permeability studies.
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Methods
Purification of A A and A ' fibrinogen
The A A and A ' fibrinogen variants were purified from human plasminogen-depleted fibrinogen using anion-exchange chromatography (Millipore, Billerica, MA) as previously described 22, 23 . Detailed description of the method can be found in Supplementary Material.
Human RBCs isolation
Blood from healthy donors was obtained, with written informed consent, at the Instituto 
Magnetic tweezers
To examine the viscoelastic properties of the fibrin clots, magnetic tweezers were used. The magnetic microrheometer operates by applying a force of 40 pN to a 4.5 µm superparamagnetic bead (Dynabeads M-450 Epoxy, Invitrogen, Paisley, UK) using a magnetic field gradient generated by four electromagnets in 2D directions. The device was used coupled with an
Olympus IX71 inverted microscope (Olympus, UK) incorporating an ultralong working objective (40× magnification) and a CCD camera. Particle tracking, electromagnet control and image analysis were performed in real time using custom written Labview 7.1 software (National Instruments, Newbury, UK). Fibrin clots were formed with and without RBCs. The viscoelastic properties were measured using the procedure of Evans et al.
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. The parameters G', G'' and Tan were calculated at a frequency of 0.1 Hz. The displacement of 8 random magnetic beads was measured per sample, and each sample was studied at least in triplicate. Please find detailed description in Supplementary Material.
Fibrin clot permeability
To study the clot permeability, samples were prepared in triplicate, according to the 
Scanning electron microscopy
Scanning electron microscopy (SEM) was used to further investigate the structure of clots formed with A A and A fibrinogen in the presence or in the absence of RBCs.
Clots were generated by adding 100 µl of A A and A ' fibrinogen variants (final concentration of 1 mg/ml) to 10 µl of activation mixture (human thrombin 1 U/ml and 10 mM CaCl 2 , final concentrations, in TBS (50 mM Tris, 100 mM NaCl, pH 7.5)). All details of the procedure are described in Supplementary Material.
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Laser scanning confocal microscopy
Fibrin clots were prepared according the procedure described in Supplementary Material. Three random areas of the clot were visualized under higher magnification. β0 m optical z-stacks were obtained and projected into 2D images. In order to obtain 3D images of the fibrin clots, 40 m z-stacks were also performed. Confocal microscopy was also used to assess, in real time, the rate of fibrinolysis following the procedure also described in Supplementary Material.
Statistical Analysis
Descriptive statistics are given as mean ± standard error of mean (SEM). Unpaired Student's ttest was used for statistical analysis of comparisons between two groups. Non-parametric analysis was also performed in cell-cell adhesion data, applying the Mann Whitney U test. Pvalues below 0.05 were considered to indicate statistical significance. Statistical analyses were performed using GraphPad Prism 5 (La Jolla, CA, USA).
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Results
RBC-RBC adhesion is altered in the presence of fibrinogen variants
Atomic force microscopy experiments were performed to investigate RBC cell-cell adhesion and the influence of A ' and A A fibrinogen variants in the cells adhesion. We evaluated the interaction between RBCs, in the presence of different concentrations of A A and A ' fibrinogen variants, up to1.0 mg/ml, by force-distance retract curves ( Figure 1 ).
AFM data showed that, in the presence of low concentrations of A ' fibrinogen, the work (thermodynamic parameter corresponding to the area under the curve on a force × distance plot, β0γ.7 ± 0.70 pN for A ', p < 0.0001; for 0.7 mg/ml fibrinogen, 141.β ± 5.γ5 pN for A A vs.
170.3 ± 0.95 pN for A ', p < 0.0001; and, for 1 mg/ml fibrinogen, 18β.9 ± 9.80 pN for A A vs. β05.5 ± 1.90 pN for A ', p = 0.0054). With the exception of the data obtained for 0.4 mg/ml fibrinogen, the values of maximum detachment force obtained for A A fibrinogen were always lower than those of A ' fibrinogen.
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After the initial maximum detachment force, two types of jumps could be observed on the force curves ( Figure 1B) : jumps preceded by a ramp of force or jumps preceded by a force plateau.
We considered a membrane tether as a step in force detected after a force plateau of 0.25 µm in distance. Jump events were assigned to the unbinding of membrane ligand-receptor interactions without a preceding membrane deformation, while membrane tether events corresponded to situations where a membrane tether was extruded before the unbinding of the ligand-receptor complex ( Figure 1B ) 35 . A combination of each of the parameters extracted from the forcedistance curves (maximum detachment force, number of jumps events/curve × mean force of jumps and number of membrane tethers events × mean force of tethers) could be considered as the value of the work needed to detach one cell from another. Similarly to the values of work ( Figure 1C ), the same profile is observed for the values of force of jumps and membrane tethers events with increasing fibrinogen concentrations when comparing both fibrinogen variants As depicted in Figure 1E ,F, at lower fibrinogen concentrations, jumps and membrane tethers displayed higher forces for A ' fibrinogen, when compared to A A variant, both for 0. 
RBCs influence A ' fibrin clot mechanical properties
The viscoelastic properties of A A and A ' fibrin clots were examined using a magnetic microrheometer and the influence of RBCs was studied. In agreement with previous findings (panels B, D and F), it can be noticed that A ' fibrin clots contained more free fiber ends and there were more fiber-to-RBC points of connections, when compared to A A fibrin clots, resulting in "clustered" cell arrangements.
In order to measure the diameter of the fibers, twenty fibers from 25000× magnification images were assessed on 2 different clots from each condition and in 3 different zones of the clot. 
Increased fibrinolytic resistance of A ' fibrin clots in the presence of RBCs
We used laser scanning confocal microscopy to study clot structure and resistance to fibrinolysis in the presence and absence of RBCs for each fibrin variant. Figure 6 shows representative examples of the confocal micrographs obtained for fiber clots made with A A and A ' purified fibrinogen variants. In clots formed with A A fibrinogen, the area occupied by the fibers seems to be larger ( Figure 6A ) than for the clots with A ' fibrinogen ( Figure 6B ). However, these differences were not statistically significant. In agreement with SEM imaging and with previous studies 22 , there was a clear difference between the structures of A A and A ' fibrin. The A A fibrin clots were composed of longer and straighter fibers than A ' fibrin clots. The later showed fibers that were shorter and clustered,
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13 producing larger pores. However, we did not find differences regarding the fiber density comparing A A with A ' fibrin clots ( Figure S2 ).
Relevant was to study the micrographs of fibrin clots from A A and A ' fibrinogen variants
in the presence of 2% of RBCs, as shown on Figure 6 (C,D) . In the presence of A A fibrinogen, the network of the fibers seemed straighter and denser. In clots with A ' fibers, we observed that the fibers were more clustered and the RBCs were more visible. We also studied fibrin clots in the presence of 5% and 10% of RBCs by LSCM; however, the high number of Finally, we studied fibrinolysis of clots made with both fibrinogen variants ( Figure 7 ). In line with previous studies 21 , a significant increase in lysis time was observed for A ' compared with A A fibrin clots (15.82 ± 1.48 min vs. 10.54 ± 0.44 min, respectively; p = 0.0267).
During the experiment, we observed a non-uniform lysis of the A ' fibrin clot, taking more time to achieve complete lysis than the A A clot (videos in Supplementary information).
We measured the lysis time for A A and A ' clots in the presence of 5% (data not shown) and According with previous studies 22, 23 , SEM and confocal microcopy showed that the clots formed by A A and A ' fibers have a different structure. The incorporation of RBCs has an important impact on fibrin fiber size and in its network structure. Regions of higher and lower RBC density were clearly visible in the clots made with ' fibrinogen. In the presence of RBCs, the ' fibrin clots were more heterogeneous, seeming to form a looser structure when compared with the clots of A fibrinogen. These findings are supported by our AFM data. At high A ' fibrinogen concentrations, the work necessary to detach two RBCs was the same that the one achieved in the presence of A A fibrinogen. In agreement with this, the clot might become looser, with a higher ability to deform and embolise, eventually blocking a downstream blood capillary.
The A ' fibrin clots contain a large number of free fiber ends. Fiber ends are normally found at low levels in scanning electron micrographs of fibrin clots, and have been suggested to arise from early truncation of protofibril formation or lateral aggregation 42, 43 . It was previously proposed that the negative charge of A ' fibrinogen on the D-D interface may disrupt oligomerization and, therefore, interrupt the continuous growth of the protofibril, leading to highly branched fibers 44, 45 .
This study has shown that the incorporation of RBCs into the clot affects fibrin fiber formation.
RBCs induced thinning of fibers in fibrin clots formed with A A, but not with A ' fibrinogen.
However, in the presence of RBCs, A A fibers remained significantly thicker than A ' fibers.
Here, we could conclude that thinner fibrin fibers (such as A ' fibrin fibers) form highly Previous studies indicated that fibrin clots with increased fiber branching and resistance to fibrinolysis are a risk factor for thrombosis 15 . Fibrinolysis data showed that the lysis time of a A ' fibrin clot is longer than for a A A clot, as already reported 4, 5 . The presence of RBCs seems to increase the lysis time. However these studies were conducted with a 10% hematocrit, where their diffusion may be increased. It was suggested that the slower lysis of ' clots is due to delayed fibrinopeptide B release, leading to a delay of plasminogen binding and activation 21 .
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Some of these findings may provide a mechanism underpinning the epidemiological data suggesting that a high ratio between A ' and A A fibrinogen variants may be a risk factor for thrombotic disease 7, 8, 9 . Further studies on the prothrombotic nature of RBCs and on fibrinogen variants are necessary to fully understand the contribution of the ' chain and RBCs to different etiologies of thrombotic diseases.
In conclusion, the incorporation of RBCs into a fibrin clot significantly affects the clot structure and its mechanical properties. RBCs interact differently with clots made with -chain fibrinogen splice variants, which may explain some of the cardiovascular clinical associations that have been reported with these fibrinogen variants. 
